Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus

Journal of Clinical Oncology

Volumn 23, Issue 10, 2005, Pages 2310-2317

  Stahl, Michael ^a   Stuschke, Martin ^a   Lehmann, Nils ^a   Meyer, Hans Joachim ^a   Walz, Martin K ^a   Seeber, Siegfried ^a   Klump, Bodo ^a   Budach, Wilfried ^a   Teichmann, Reinhard ^a   Schmitt, Marcus ^a   Schmitt, Gerd ^a   Franke, Claus ^a   Wilke, Hansjochen ^a  

^a KLINIKEN ESSEN MITTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; FLEP REGIMEN; VP P PROTOCOL; VP-P PROTOCOL;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; ESOPHAGUS CARCINOMA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; ADJUVANT THERAPY; ESOPHAGUS TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHASE 3 CLINICAL TRIAL; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ETOPOSIDE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; SURVIVAL ANALYSIS;

EID: 20244387586     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.00.034     Document Type: Article

References (23)

1. Jemal A, Murray T, Samuels A, et al: Cancer statistics, 2003. CA Cancer J Clin 53:5-26, 2003
2. Siewert JR, Stein HJ, Feith M, et al: Histologic tumor type is an independent prognostic parameter in esophageal cancer: Lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg 234:360-369, 2001
3. Cooper JS, Guo MD, Herskovic A, et al: Chemoradiotherapy of locally advanced esophageal cancer. JAMA 281:1623-1627, 1999
4. Wong R, Malthaner R: Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus (Cochrane Review), in The Cochrane Library, Issue 1, 2003. Oxford, Update Software
5. Kelsen DP, Ginsberg R, Pajak TF, et al: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339:1979-1984, 1998
6. Medical Research Council Oesophageal Cancer Working Party: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet 359:1727-1733, 2002
7. Kaklamanos I, Walker G, Kristian F, et al: Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: A meta-analysis of randomized clinical trials. Ann Surg Oncol 10:754-761, 2003
8. Urschel JD, Vasan H, Blewett CJ: A metaanalysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg 183:274-279, 2002
9. Malthaner R, Fenlon D: Preoperative chemotherapy for resectable thoracic esophageal cancer (Conchrane Review), in The Conchrane Library, Issue 4, 2003. Chichester, United Kingdom, John Wiley & Sons, Ltd, 2003
10. Urschel JD, Vasan H: A meta-analysis for randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 185:538-543, 2003
11. Fiorica F, Di Bona D, Schepis F, et al: Preoperative chemoradiotherapy for oesophageal cancer: A systematic review and metaanalysis. Gut 53:925-930, 2004
12. Stahl M, Wilke H, Fink U, et al: Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer: Interim analysis of a phase II trial. J Clin Oncol 14:829-837, 1996
13. Hermanek P, Sobin LH (eds): TNM Classification of Malignant Tumours (ed 4, 2nd revision). Berlin, Germany, Springer, 1992, pp 40-42
14. Bauer P, Köhne K: Evaluation of experiments with adaptive interim analyses. Biometrics 50:1029-1041, 1994
15. Wellek S: A log-rank test for equivalence of two survivor functions. Biometrics 49:877-881, 1993
16. Geh JI, Crellin AM, Glynne-Jones R: Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg 88:338-356, 2001
17. Enzinger PC, Mayer RJ: Esophageal cancer. N Engl J Med 349:2241-2252, 2003
18. Van Lanschot JB, Hulscher JBF, Buskens CJ, et al: Hospital volume and hospital mortality for esophagectomy. Cancer 91:1574-1578, 2001
19. Birkmeyer JD, Siewers AE, Finlayson EVA, et al: Hospital volume and surgical mortality in the United States. N Engl J Med 346:1128-1137, 2002
20. Minsky BD, Pajak TF, Ginsberg RJ, et al: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol 20:1167-1174, 2002
21. Geh JI, Bond SJ, Bentzen SM, et al: Preoperative chemoradiotherapy in esophageal cancer: Evidence of dose response. Proc Am Soc Clin Oncol 19:247a, 2000 (abstr 958)
22. Okawa T, Dokiya T, Nishio M, et al: Multiinstitutional randomized trial of external radiotherapy with and without intraluminal brachytherapy for esophageal cancer in Japan: Japanese Society of Therapeutic Radiology and Oncology (JASTRO) Study Group. Int J Radiat Oncol Biol Phys 45:623-628, 1999
23. Bedenne L, Michel P, Bouche O, et al: Randomized phase III trial in locally advanced esophageal cancer: Radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102). Proc Am Soc Clin Oncol 21:130a, 2002 (abstr 519)